{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"* Defined as the interval from the first documentation of objective response (complete response or partial response) to the earlier of the first documentation of disease progression or death from any cause\n* Intracranial disease: response and progression will be evaluated using the updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology (RANO) working group guideline","groups":[{"description":"-MEDI4736 will be given to all patients \\> 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients \\< 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.","id":"OG000","title":"Cohort A: Non-small Cell Lung Cancer w/o Corticosteroids"},{"description":"-MEDI4736 will be given to all patients \\> 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients \\< 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.","id":"OG001","title":"Cohort B: Epithelial Origin Solid Tumors w/o Corticosteroids"},{"description":"-MEDI4736 will be given to all patients \\> 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients \\< 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.","id":"OG002","title":"Cohort C: NSCLC or Non-NSCLC w/Corticosteroids"}],"populationDescription":"None of the participants in Cohort A were evaluable for this outcome measure as they did not have an objective response per RANO guidelines. There were not any participants enrolled to Cohort B or Cohort C.","reportingStatus":"POSTED","timeFrame":"Completion of treatment (estimated to be 6 months)","title":"Duration of Response of Intracranial Disease","type":"SECONDARY"}